A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

Exclusion Criteria

• •Occurrence of a cardiovascular event \< 6 months prior to screening
• •Pregnant, planning to become pregnant during the study, or breastfeeding
• •Clinically significant abnormal laboratory values or abnormal ECG or vital signs
• •History of anaphylactic reactions
• •Newly discovered Type 2 diabetes mellitus (T2DM) (prior to study entry) or medical treatment for T2DM started \< 3 months prior to study entry
• •Use of insulin, corticosteroids (oral, rectal, or injectable), or other immunosuppressive medications
• •Current or recent (within 4 weeks prior to screening) infection, including signs, symptoms or serology of any infection, including HIV, hepatitis B or C
• •Impaired renal function
• •History of malignancy within 2 years prior to screening
• •Current life-threatening condition other than vascular disease that may prevent a patient from completing the study
• •Use of an investigational drug or biologic within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study medication
• •Exposure to substantial radiation within 12 months prior to screening